Aprea Therapeutics (APRE) Stock Chart & Stock Price History → The Weight Loss Pill That Could Disrupt a $32 Billion Industry (From Behind the Markets) (Ad) Free APRE Stock Alerts $5.14 -0.04 (-0.77%) (As of 05/8/2024 ET) Add Compare Share Share ChartStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Aprea Therapeutics Stock Price Performance5 Day Performance-0.93%1 Month Performance-9.25%3 Month Performance-22.96%6 Month Performance+30.22%Year-To-Date Performance+12.77%1 Year Performance+34.52% Receive APRE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter Email Address Ad Behind the MarketsCould this Tiny Biotech End Disease Forever?Imagine a revolutionary treatment capable of editing out ANY disease. By literally "cutting" the genetic instructions that cause illness, and "pasting" in corrected DNA to restore perfect health.Access my full "Cut & Paste" profit analysis now. APRE Stock Chart for Wednesday, May, 8, 2024 APRE Chart by TradingView Aprea Therapeutics Share Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization05/07/2024$5.26$5.17-1.71%$5.35$5.175,137 shs$28.07 million05/06/2024$5.35$5.26-1.68%$5.35$5.253,460 shs$28.56 million05/03/2024$5.45$5.35-1.83%$5.45$5.352,249 shs$29.05 million05/02/2024$5.25$5.45+3.81%$5.45$5.332,195 shs$29.59 million05/01/2024$5.10$5.25+2.94%$5.25$5.102,971 shs$28.51 million04/30/2024$5.08$5.10+0.31%$5.17$4.9014,870 shs$27.69 million Get the Latest News and Ratings for APRE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 04/29/2024$5.20$5.08-2.23%$5.26$5.002,551 shs$27.61 million04/26/2024$5.35$5.20-2.80%$5.20$5.004,833 shs$28.24 million04/25/2024$5.07$5.35+5.52%$5.47$5.029,079 shs$29.05 million04/24/2024$5.37$5.07-5.59%$5.37$5.066,305 shs$27.53 million04/23/2024$5.16$5.37+4.07%$5.62$5.142,607 shs$29.16 million04/22/2024$5.35$5.16-3.55%$5.75$5.1211,827 shs$28.02 million04/19/2024$5.84$5.41-7.36%$5.79$5.317,280 shs$29.38 million04/18/2024$5.73$5.84+1.92%$5.84$5.61873 shs$31.71 million04/17/2024$5.70$5.73+0.53%$5.85$5.712,289 shs$31.11 million04/16/2024$5.93$5.70-3.88%$5.95$5.705,097 shs$30.95 million04/15/2024$5.71$5.93+3.85%$6.01$5.718,448 shs$32.20 million04/12/2024$5.90$5.93+0.51%$6.23$5.694,652 shs$32.20 million04/11/2024$6.20$5.90-4.84%$6.16$5.853,480 shs$32.04 million04/10/2024$6.04$6.20+2.66%$6.20$5.326,281 shs$33.67 million04/09/2024$5.84$6.04+3.41%$6.31$5.906,614 shs$32.79 million04/08/2024$6.30$5.84-7.30%$6.40$5.8211,661 shs$31.71 million04/05/2024$6.17$6.30+2.11%$6.48$6.009,848 shs$23.56 million04/04/2024$6.31$6.17-2.22%$6.48$6.0116,915 shs$23.08 million04/03/2024$6.60$6.31-4.39%$6.70$6.3010,211 shs$23.60 million04/02/2024$6.63$6.60-0.45%$6.60$6.2110,056 shs$24.68 million04/01/2024$6.69$6.63-0.90%$6.64$6.134,887 shs$24.80 million03/29/2024$6.69$6.69$6.80$5.9128,785 shs$25.02 million03/28/2024$6.07$6.69+10.21%$6.80$5.9128,419 shs$25.02 million03/27/2024$5.92$6.07+2.53%$6.31$5.9516,742 shs$22.70 million03/26/2024$6.08$5.92-2.63%$6.12$5.9210,133 shs$22.14 million03/25/2024$6.12$6.08-0.65%$6.20$5.9510,833 shs$22.74 million03/22/2024$6.35$6.12-3.62%$6.20$6.005,207 shs$22.89 million03/21/2024$6.50$6.35-2.31%$6.63$5.8851,594 shs$23.75 million03/20/2024$6.74$6.50-3.56%$6.74$6.484,024 shs$24.31 million03/19/2024$6.55$6.74+2.90%$6.88$6.5515,769 shs$25.21 million03/18/2024$6.19$6.55+5.82%$6.79$5.7928,291 shs$24.50 million03/15/2024$5.43$6.19+14.00%$6.20$5.5833,864 shs$23.15 million03/14/2024$5.55$5.43-2.16%$5.87$5.0528,241 shs$20.29 million03/13/2024$6.16$5.55-9.90%$6.26$5.5526,363 shs$20.74 millionThe Weight Loss Pill That Could Disrupt a $32 Billion Industry (Ad)A revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.Don't miss out on the "next Ozempic" >>>03/12/2024$6.77$6.16-9.01%$6.76$6.1651,852 shs$23.04 million03/11/2024$7.13$6.77-5.05%$8.10$6.271.15 million shs$25.32 million03/08/2024$7.45$7.13-4.30%$7.63$7.094,081 shs$26.67 million03/07/2024$8.29$7.45-10.13%$8.40$7.4028,563 shs$27.86 million03/06/2024$8.17$8.29+1.47%$8.29$8.091,782 shs$31.01 million03/05/2024$8.40$8.17-2.74%$8.40$7.3013,162 shs$30.56 million03/04/2024$8.00$8.40+5.00%$8.40$7.657,414 shs$31.42 million03/01/2024$8.46$8.00-5.44%$8.85$7.7228,900 shs$29.92 million02/29/2024$7.20$8.46+17.50%$8.49$7.3514,461 shs$31.64 million02/28/2024$7.16$7.20+0.56%$7.28$7.152,289 shs$26.93 million02/27/2024$7.15$7.16+0.14%$7.48$6.8319,569 shs$26.78 million02/26/2024$7.24$7.15-1.24%$7.50$7.0714,206 shs$26.74 million02/23/2024$6.37$7.20+12.97%$7.50$6.4719,060 shs$26.93 million02/22/2024$6.28$6.37+1.49%$6.40$6.203,385 shs$23.84 million02/21/2024$6.13$6.28+2.45%$6.28$6.28593 shs$23.49 million02/20/2024$5.83$6.13+5.15%$6.28$5.5722,718 shs$22.93 million02/19/2024$5.83$5.83+0.03%$6.10$5.503,300 shs$21.80 million02/16/2024$5.68$5.59-1.58%$6.10$5.503,316 shs$20.91 million02/15/2024$5.97$5.68-4.86%$6.13$5.506,484 shs$21.23 million02/14/2024$6.17$5.97-3.24%$6.18$5.5110,249 shs$22.31 million02/13/2024$6.40$6.17-3.59%$6.63$5.9120,657 shs$23.08 million02/12/2024$6.00$6.40+6.67%$6.47$6.334,248 shs$23.94 million02/09/2024$6.88$6.00-12.79%$6.73$6.005,515 shs$25.71 million02/08/2024$6.62$6.88+3.93%$6.88$6.059,771 shs$25.73 million02/07/2024$7.35$6.62-9.93%$7.71$6.4215,519 shs$24.76 million Related Companies: FBRX Stock Chart SPRB Stock Chart ACST Stock Chart UBX Stock Chart DRRX Stock Chart NRXP Stock Chart SNSE Stock Chart ITRM Stock Chart LPCN Stock Chart BFRG Stock Chart Receive APRE Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:APRE) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressHe Is Giving Away BitcoinCrypto Swap ProfitsThe AI Stock that’s Disrupting Every IndustryStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aprea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.